User:Mr. Ibrahem/Certolizumab pegol

Certolizumab pegol, sold under the brand name Cimzia, is a medication used to treat Crohn's disease, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. It is given by injection under the skin.

Common side effects include infections such as abscesses, low white blood cells, nausea, headache, numbness, high blood pressure, liver inflammation, rash, and pain at the site of injection. Other side effects may include cancer, heart failure, and angioedema. It is a fragment of a monoclonal antibody that binds to tumor necrosis factor alpha (TNF-α).

Certolizumab pegol was approved for medical use in the United States in 2008 and Europe in 2009. It is on the World Health Organization's List of Essential Medicines as an alternative to adalimumab. In the United Kingdom 400 mg costs the NHS about £715 as of 2021. This amount in the United States costs about 4,700 USD.